CAGNONI PABLO J — SEC insider filings
SEC reporting owner CIK 1205703. 31 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2021-02-02 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 13 filings — 155,054 shares, $14,767,603 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 77.
- Largest priced transaction: sale of 15,888 shares @ $119.70 ($1,901,794) in INCYTE CORP, filed 2026-08-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| INCYTE CORP (INCY) | President, Global Head of R&D | 23 | — | 12 legs · 132,636 sh · $14,719,510 | 59 |
| Rubius Therapeutics, Inc. (RUBY) | Director | 4 | — | 3 legs · 22,418 sh · $48,093 | 10 |
| Fusion Pharmaceuticals Inc. (FUSN) | Director | 4 | — | — | 8 |
Insider filings — CAGNONI PABLO J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | INCYTE CORP (INCY) | Option exercise (M): 455 @ $61.18 · Option exercise (M): 422 @ $61.76 · Option exercise (M): 926 @ $64.25 · Option exercise (M): 839 @ $71.93 · Sale (S): 877 @ $121.98 · Sale (S): 1,765 @ $120.46 · +4 more | EDGAR |
| 2026-10-19 | 4 | INCYTE CORP (INCY) | Option exercise (M): 839 @ $71.93 · Option exercise (M): 423 @ $61.76 · Option exercise (M): 455 @ $61.18 · Option exercise (M): 925 @ $64.25 · Sale (S): 2,642 @ $112.71 · Option exercise (M): 839 (derivative) @ $0 · +3 more | EDGAR |
| 2026-09-17 | 4 | INCYTE CORP (INCY) | Option exercise (M): 2,957 @ $61.76 · Option exercise (M): 4,551 @ $61.18 · Option exercise (M): 6,477 @ $64.25 · Option exercise (M): 9,233 @ $71.93 · Sale (S): 9,233 @ $120.50 · Sale (S): 13,985 @ $120.49 · +4 more | EDGAR |
| 2026-08-20 | 4 | INCYTE CORP (INCY) | Sale (S): 10,801 @ $125.56 | EDGAR |
| 2026-08-14 | 4 | INCYTE CORP (INCY) | Sale (S): 10,803 @ $120.04 | EDGAR |
| 2026-08-07 | 4 | INCYTE CORP (INCY) | Sale (S): 10,640 @ $122.69 | EDGAR |
| 2026-08-04 | 4 | INCYTE CORP (INCY) | Sale (S): 15,888 @ $119.70 | EDGAR |
| 2026-07-20 | 4 | INCYTE CORP (INCY) | Grant/award (A): 13,403 @ $0 · Grant/award (A): 33,508 (derivative) @ $0 · Grant/award (A): 57,861 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 17,969 @ $114.88 · Tax withholding (F): 4,950 @ $115.09 | EDGAR |
| 2026-06-03 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 25,469 @ $95.59 | EDGAR |
| 2026-05-20 | 4/A | INCYTE CORP (INCY) | Grant/award (A): 31,517 @ $0 | EDGAR |
| 2026-04-21 | 4 | INCYTE CORP (INCY) | Option exercise (M): 6,077 @ $64.25 · Option exercise (M): 12,590 @ $71.93 · Sale (S): 18,667 @ $96.50 · Option exercise (M): 6,077 (derivative) @ $0 · Option exercise (M): 12,590 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 27,892 @ $0 | EDGAR |
| 2026-03-19 | 4 | INCYTE CORP (INCY) | Option exercise (M): 7,166 @ $61.18 · Option exercise (M): 11,501 @ $64.25 · Sale (S): 18,667 @ $94.24 · Option exercise (M): 7,166 (derivative) @ $0 · Option exercise (M): 11,501 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | INCYTE CORP (INCY) | Option exercise (M): 13,093 @ $61.76 · Option exercise (M): 5,575 @ $61.18 · Sale (S): 18,668 @ $100.91 · Option exercise (M): 13,093 (derivative) @ $0 · Option exercise (M): 5,575 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | INCYTE CORP (INCY) | Grant/award (A): 28,475 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | INCYTE CORP (INCY) | Tax withholding (F): 1,280 @ $69.98 · Tax withholding (F): 2,628 @ $68.25 · Grant/award (A): 17,538 @ $0 · Grant/award (A): 43,846 (derivative) @ $0 · Grant/award (A): 39,471 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | INCYTE CORP (INCY) | Grant/award (A): 40,289 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 19,851 @ $0 · Tax withholding (F): 749 @ $64.25 · Grant/award (A): 44,411 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 141,011 (derivative) | EDGAR |
| 2024-01-22 | 4 | INCYTE CORP (INCY) | Grant/award (A): 21,843 (derivative) @ $0 | EDGAR |
| 2023-07-18 | 4 | INCYTE CORP (INCY) | Grant/award (A): 9,668 @ $0 · Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4/A | INCYTE CORP (INCY) | Grant/award (A): 192,400 @ $0 | EDGAR |
| 2023-06-14 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | INCYTE CORP (INCY) | Grant/award (A): 179,613 @ $0 | EDGAR |
| 2023-02-01 | 4 | Rubius Therapeutics, Inc. (RUBY) | Sale (S): 8,448 @ $0.25 | EDGAR |
| 2023-01-31 | 4 | Rubius Therapeutics, Inc. (RUBY) | Option exercise (M): 21,250 · Option exercise (M): 25,000 · Sale (S): 7,240 @ $0.24 · Option exercise (M): 21,250 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Rubius Therapeutics, Inc. (RUBY) | Option exercise (M): 21,250 · Sale (S): 6,730 @ $6.57 · Option exercise (M): 21,250 (derivative) @ $0 · Grant/award (A): 365,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Rubius Therapeutics, Inc. (RUBY) | Grant/award (A): 375,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1205703 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs